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Health Trajectories in People with Cystic
Fibrosis in the UK: Exploring the Effect
of Social Deprivation
David Taylor-Robinson, Peter Diggle, Rosalind Smyth,
and Margaret Whitehead
Cystic Fibrosis As a Case for Studying Health Inequalities
Exploring the reasons for inequalities in outcomes in people with cystic fibrosis
(CF) offers a unique opportunity to develop our understanding around pathways
in inequalities in health more generally. Because CF is genetically determined, a
socio-economic difference in incidence is not expected, but there may be important
differences in outcomes over the course of people’s lives.
Studies across the world have consistently shown that people from socio-
economically disadvantaged backgrounds experience worse health than those in
more socio-economically advantaged positions. These inequalities in health out-
comes are preventable, amenable to policy intervention, and they are unjust. In
the UK and internationally, policies are being implemented to try to reduce health
inequalities, with limited success, since for many important health outcomes, such
as life expectancy in the UK, despite continuing overall improvements, significant
inequalities remain (Marmot et al. 2010; Barr et al. 2012). In order to develop more
effective interventions, we need a better understanding of how, and when, these
health differences are generated and maintained.
This chapter brings together findings from our previously published longitudinal
registry studies examining the effect of social deprivation on longitudinal clinical
outcomes, healthcare use and employment opportunities in people with cystic
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fibrosis (CF), and draws on material from the lead author’s PhD thesis, from
which some sections are reproduced (Taylor-Robinson 2013; Taylor-Robinson et al.
2013a, b). Studying the health of people with CF in this way provides a valuable case
study to investigate the impact of social deprivation on health and social outcomes,
in a chronic condition without a socio-economic gradient in incidence. Despite this
‘level playing field’ at the outset, the processes by which differential outcomes in
CF are generated are unclear. Elucidating these mechanisms is important to inform
policies, both to improve care in CF, and to reduce inequalities in health more
broadly.
Key Features of Cystic Fibrosis
CF is an inherited, chronic, progressive condition occurring in around 1 in 2500
live births in the UK, and affecting over 9000 individuals, with around 300 new
diagnoses annually (Dodge et al. 2007; CF Trust 2013). CF is the commonest serious
inherited disease among white populations, and is caused by mutations in the CF
transmembrane conductance regulator (CFTR) gene, resulting in thick secretions
that impair various organs, particularly the respiratory and digestive systems. It is
an autosomal recessive condition; inheritance requires receiving two copies of the
defective CFTR gene, one from each parent (Davies et al. 2007). Most children
are diagnosed in the first few months of life, and subsequently require intensive
support from family and health care services. Most patients die prematurely from
their disease through respiratory failure, but with increasing survival into adulthood,
CF is best understood as a complex, multisystem disease.
Survival beyond the first few years of life was rare in the 1940s, but UK children
born in the twenty-first century are now estimated to have a median survival of
over 50 years of age (Dodge et al. 2007). Survival in CF has increased under the
influence of improved treatment and management, improved nutrition and better
living conditions (Davies et al. 2007; Schechter 2004), but these improvements do
not appear to have been shared equally, since studies in both the US and UK have
demonstrated differences in survival by socio-economic status (SES) (Schechter
et al. 2001; O’Connor et al. 2003; Britton 1989). The social patterning of survival
in CF suggests that social factors – the ‘social determinants of health’ – are having
an important effect on outcomes. Utilising some of the unique characteristics of CF
to explore the causes of these differences can offer broader insights.
CF is thus an interesting case conceptually for the study of pathways to
inequalities in health: as a disease of autosomal recessive inheritance where carriers
are unaffected, there is no social bias in incidence (Fig. 5.1), but there is potential
for a social gradient in health care use, disease outcome, and social consequences to
develop. CF thus opens up opportunities for inequalities research, because it offers
both homogeneity, in terms of the population affected by the disease at the outset,
and yet great variation in outcomes that can be explored. These two characteristics
make for a promising “tracer condition” to improve our understanding of pathways
to differential outcomes.
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Fig. 5.1 Distribution of incident cases of CF in the UK by deprivation quintile 1996–2010. Error
bars represent 95 % binomial CIs (n D 2066) (Source: Adapted from Taylor-Robinson et al. 2013b)
Clinical Management of CF
Describing the management of CF in any depth is beyond the scope of this chapter,
but for a succinct review see Davies and colleagues (2007). In brief, the key
treatment outcomes considered in the analysis relate to respiratory and nutritional
therapies:
• Treatment of respiratory infections with antibiotics is a central pillar of CF
therapy including for prophylaxis; eradication of infections; long-term treatment
of chronic infection, and treatment of acute exacerbations. The aim is to
prevent initial bacterial infection in children, and promptly treat acute infections
using antibiotics. Acute chest infections (exacerbations) are treated with oral,
nebulised, and/or IV antibiotics.
• DNase is an inhaled mucolytic that breaks down the thick sputum in the lungs.
This was first commercially available in 1992, and was the first treatment to
demonstrate an improvement in lung function in CF (Fuchs et al. 1994).
• The main aims of nutritional support in CF are to achieve optimal nutritional
status, and allow normal growth and development throughout childhood. Pancre-
atic enzyme insufficiency leads to malabsorption of fats, diarrhoea, and failure
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to thrive, and this is compounded by lung disease and infection, which further
increases calorie requirements. Thus recommendations are for early nutritional
support with adequate pancreatic replacement management, as this has been
shown to improve growth and subsequent lung function (Konstan et al. 2003;
Munck et al. 2009).
Previous Research on Health Inequalities and CF
People with CF from more disadvantaged groups in the UK and US die earlier
than those from more advantaged backgrounds. In the UK, the first study to look
at social differences in survival in CF found a consistent trend from 1959 to 1986
towards higher age at death in CF patients in more advantaged social groups on the
basis of occupational class (Britton 1989). The authors speculated that the observed
lower survival chances in lower social classes could relate to lack of access to
the appropriate services, poorer nutrition, increased parental smoking, and poorer
quality housing.
Evidence from the US corroborated these findings, and indicated higher survival
rates in the 1980s and 1990s among more advantaged socio-economic groups,
measured by Medicaid status and area-based income, compared with their less
advantaged counterparts (Schechter et al. 2001; Schechter 2004; O’Connor et al.
2003). For instance the adjusted risk of death was around four times higher in CF
patients with Medicaid cover (used as a surrogate for poverty) compared to those
without Medicaid cover (Schechter et al. 2001). Two studies from the US showed
differences in lung function on the basis of measures of SES. For instance Schechter
et al. also showed significantly lower percent predicted forced expiratory volume in
one second (%FEV1) at age 5 in the Medicaid patients (9.2 percentage points, 95 %
CI 7.1–11.4), and this gap increased slightly in an age dependent manner up to age
20. O’Connor et al. extended the work of Schechter’s team by demonstrating a social
gradient in the relationship between area-based income in the US, and mortality
rates, lung function and weight (O’Connor et al. 2003). The authors point out the
limitations of the ecological (area-based) measure of SES used in their analysis, and
suggest that the associations observed may be due to poor adherence to medications,
or local environmental conditions.
In many chronic illnesses, differences in access to specialist health care by
SES are evident. These differences often contribute to the exacerbation of health
inequalities, since a bias towards more advantaged groups is widespread across
health care (Stirbu et al. 2011). This could be particularly important in the context
of inequalities in outcomes for a disease like CF, where treatment advances have
had such a profound effect on survival. The studies exploring access to services
and treatments in CF have been predominantly from the US, and have demonstrated
a mixed picture, depending on the type of treatment under consideration, and the
exact measure of SES used (O’Connor et al. 2003; Schechter et al. 2009, 2011). For
instance, one study showed greater access to intravenous (IV) antibiotics for older
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children, on the basis of area-based income, but also showed no difference in access
to DNase, another important treatment in CF, using Medicaid status as a measure
of SES (Schechter et al. 2009). Overall the US studies have played down the role
of health service factors in the generation of health disparities in CF. However, it
is debatable how much of this evidence can be generalized to other health care
settings, especially to the UK context, where access to health services is free at the
point of use.
Using the Diderichsen Model to Study Inequalities in CF
Outcomes in the UK
To gain a better understanding of when and how inequalities in outcomes develop
in cystic fibrosis in a UK context, the studies summarised in the subsequent sections
of this chapter explored the effect of deprivation on growth, nutrition, lung function,
risk of Pseudomonas aeruginosa colonisation, and the use of major cystic fibrosis
treatment modalities in a UK-wide population cohort, in the context of a the British
NHS, a universal healthcare system, free at the point of use (Taylor-Robinson 2013;
Taylor-Robinson et al. 2013a, b).
The studies involved longitudinal analyses of individual level patient data from
the UK CF Registry, which is supported and co-ordinated by the UK CF Trust
(2013; Adler et al. 2008), and records information about the health and treatment
of patients with CF from diagnosis onwards. The Registry is estimated to include
nearly all people with CF in the UK population (Mehta et al. 2004) and is therefore
ideally suited to the study of outcomes and treatments across the whole socio-
economic spectrum in the UK society. The studies use postcodes to link individuals
to small area deprivation measures in the UK as a measure of socio-economic status
(SES), since individual level measures of patient SES, such as parental education
level, were not available. The indices of multiple deprivation combine economic,
social and housing indicators measured at the census into a fine grained composite
deprivation score for small areas in the UK constituent countries (ONS 2011).
The analyses were informed by the Diderichsen model of pathways to health
inequalities (Diderichsen et al. 2001). This model captures key concepts in our con-
temporary understanding of how health inequalities are generated, and was used as
the conceptual basis for the work of the WHO Commission for Social Determinants
of Health (CSDH 2008). The framework conceptualises the generation of health
inequalities occurring through four main pathways over the life course (Fig. 5.2):
through social stratification itself, which is the process by which people are sorted
into different social positions (for example by social inequalities in the education
system); because social stratification leads to differential exposure to risk factors
(for example children living in poverty are more likely to be exposed to second-
hand smoke in the home); differential vulnerability at the same level of exposure (for
example due to clustering of cardiovascular risk factors, smoking is more harmful
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Fig. 5.2 A conceptual model for studying the effect of social position and social context on health
(Adapted from Diderichsen et al. 2001)
to health in the presence of high blood pressure (Capewell and Graham 2010));
and differential consequences of ill health (for example less advantaged groups
who experience cardiovascular events are more likely to become unemployed than
individuals in more advantaged positions (Holland et al. 2009)).
A key feature of the Diderichsen model is that it incorporates both social
causation and social selection mechanisms within a common framework, across
the life course. Importantly, the model also explicitly links the broader social
environment to the causal pathway at the individual level and makes it clear that
the social determinants of health are policy sensitive (Taylor-Robinson 2013).
Using the Diderichsen model, the studies outlined here explored how the clinical
consequences of CF vary in the UK on the basis of SES across the life course, and
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how exposure to health damaging risk factors such as acquisition of important lung
infections, and use of major CF treatment modalities vary over time.
A neglected area of study has been the effect of SES on social outcomes in CF,
such as employment status. Understanding the social consequences of ill health is a
key step in elucidating the pathways to health inequalities, since any adverse social
outcomes that occur as a result of ill health can feedback and further damage health
status. For example, ill health might lead to job loss, which can then have further
adverse effects on health status, mediated by a range of physical and psycho-social
mechanisms. Furthermore, there is evidence from social epidemiological studies to
suggest that, in many settings, it is people from more disadvantaged backgrounds
who particularly experience adverse health outcomes as a result of ill health – so
called differential social consequences in the Diderichsen model (Milton et al. 2006;
Holland et al. 2009; Carlsen et al. 2007, 2008).
The Effect of Socioeconomic Status on Clinical Outcomes
in Cystic Fibrosis in the UK
In the UK studies, children with CF from more disadvantaged areas were shown to
have worse growth and lung function trajectories compared with children from more
affluent areas, but these inequalities did not widen with advancing age (Table 5.1).
Looking at growth in the UK CF population in more detail, Fig. 5.3 shows clinically
important differences for weight, height BMI on the basis of area deprivation. In a
longitudinal analysis, adjusting for a range of confounding factors, the difference
in weight and height standard deviation (SD) score is about one third between the
most and least advantaged quintiles, whereas for BMI the difference is about one
sixth of a standard deviation score (z-score). These results show that having CF, and
living in the most disadvantaged areas of the UK effectively doubles the nutritional
disadvantage experienced by a person with CF. The deprivation gap in weight is
greatest in the first few months of life, at the time of diagnosis, and there follows
narrowing of the gap up to around age 3 from around 0.54 SD scores (95 % CI –
0.73 to –0.34) at birth to 0.28 (95 % CI 0.38 to 0.18) at age 3, but then the gap
remains constant into adulthood (Fig. 5.4).
The finding of a social gradient in growth outcomes, evident from around
the time of diagnosis, points to important effects of deprivation in utero, and/or
in the initial period prior to diagnosis. Both are plausible, but a limitation of
studies thus far has been a lack of data on birth-weight, which would complete
the picture. The association between low SES and low birth-weight, and length
is well established in the general population (Spencer et al. 1999; Marmot et al.
2010; Howe et al. 2011, 2012). The causes for this are likely to be multi-factorial
and relate to maternal health, including stress, diet, drug, alcohol and tobacco
use during pregnancy (Marmot et al. 2010). The question remains, however, as to
how having CF modifies this relationship. Direct comparison of the SES effect on
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Table 5.1 Summary of adjusted effects of deprivation on clinical outcomes and use of therapies
in the paediatric and adult CF population in the UK
Age < 18 Age 18–40
Clinical outcomesa
Lung function as measured by
percent predicted forced
expiratory volume – %FEV1 (%)
4  12 (5  01 to 3  19) 1  6 (4  41 to 1  25)
Weight-for-age (SD score) 0  28 (0  38 to 0  18) 0  31 (0  46 to 0  16)
Height-for-age (SD score) 0  31 (0  40 to 0  21) 0  31 (0  43 to 0  19)
BMI-for-age (SD score) 0  13 (0  22 to 0  04) 0  12 (0  25 to 0  01)
OR for P. aeruginosa colonisation 1  89 (1  34 to 2  66) 1  78 (1  26 to 2  51)
Therapies
OR for any IV therapyb 2  52 (1  92 to 3  17) 1  89 (1  51 to 2  38)
Mean difference IV days per year
(%)b
15  9 (8  2 to 24) 10  6 (2  5 to 19  2)
OR for supplemental feedingc 1  78 (1  42 to 2  2) 2  38 (1  69 to 3  36)
OR for DNase therapyb 0  40 (0  21 to 0  72) 0  37 (0  26 to 0  52)
OR for inhaled antibioticsc 0  66 (0  47 to 0  93) 0  40 (0  31 to 0  5)
Source: Adapted from Taylor-Robinson et al. (2013a)
All estimates compare the most deprived quintile to the least deprived (reference) quintile. 95 %
CI in parenthesis
aThe outcomes are from separate longitudinal models adjusted for time trends, sex, genotype,
screening status and ethnicity
bAdjusted for time trends, sex, genotype, screening status, %FEV1 and P. aeruginosa colonisation
status
cAdjusted for time trends, sex, genotype, screening status and BMI SD score
growth in the CF population, and the general population is challenging, due to the
lack of studies using comparable SES measures and birth cohorts, and due to the
effect of the obesity epidemic in the general population, whereby a relationship
between overweight and low SES emerges from around age 4 onwards (Howe et al.
2011, 2012). This is in contrast to CF, where children are consistently underweight
compared to the UK reference population (Taylor-Robinson et al. 2013a). Further
data on SES gradients in birth-weight in CF would clarify the extent to which the
early growth differentials demonstrated are a reflection of the broader SES effects
on birth-weight in the general population. The narrowing of inequality in weight SD
score in the first 3 years of life is an important finding and suggests that diagnosis
and treatment for CF in the NHS may be having a pro-poor, or ‘levelling-up’ effect
on health inequalities. This has policy implications, and supports the universal
screening that has been introduced in the UK to allow earlier diagnosis (Taylor-
Robinson 2013).
Lung function, as measured by percent predicted forced expiratory volume in
one second (%FEV1) is considered one of the most important clinical outcomes in
CF, and Fig. 5.5 shows the differences between deprivation quintiles in the UK with
respect to key respiratory outcomes. In an adjusted longitudinal analysis (Table 5.1),
people from the most deprived areas had significantly worse lung function (–4.12
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Fig. 5.3 Anthropometric outcomes: mean cross-sectional weight, height, and BMI by age com-
paring extremes of deprivation quintile (red most deprived) (Adapted from Taylor-Robinson et al.
2013a)
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Fig. 5.4 Longitudinal weight trajectory in children in the UK with CF comparing extremes of
deprivation quintile. Trajectories plotted at reference values for other covariates in the regression
model: female sex, homozygote delta F508 carrier, not diagnosed by screening, white, born in 1991
(Adapted from Taylor-Robinson 2013)
Fig. 5.5 Respiratory outcomes: mean cross-sectional %FEV1 and P. aeruginosa coloniza-
tion prevalence by age comparing extremes of deprivation quintile (Adapted from Taylor-
Robinson et al. 2013a)
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percentage points, 95 % C1 –5.01 to –3.19), but the deprivation gap in %FEV1 did
not increase over the paediatric age range. The prevalence of chronic P. aeruginosa
colonisation, the key infection in CF, is also higher in people from the most deprived
areas of the UK, from an early age (OR 1.89 in the <18 age group, 95 % CI 1.34 to
2.66) (Table 5.1).
The finding of a social gradient in lung function at age 5 in the UK, when it can be
first measured on a routine basis, points to the influence of risk factors earlier in the
life course. These are likely to include both environmental and healthcare factors.
Schechter and colleagues’ found that inequalities in %FEV1 by Medicaid status
widened slightly from 5 to 20 years of age (Schechter et al. 2001) in a cross sectional
analysis. At round age 5 there was a gap of around 9 % in %FEV1 in the US
population, whereas in another study O’Connor and colleagues found a difference
of 5.5 % between most and least deprived quintiles (O’Connor et al. 2003). Due
to the methodological differences it is not possible to make a direct comparison
between UK and US findings in terms of the magnitude of the deprivation gap in
lung function (Taylor-Robinson 2013).
In the adult population, growth and P. aeruginosa outcomes were worse in the
most deprived adults, but no significant difference in lung function was detected
(Table 5.1). The lack of an association between SES and %FEV1 in the adult
population is perhaps surprising, given the tendency for social inequalities in health
outcomes to increase over time. This may relate to the differences in the use of
therapies across social groups described in the next section, or to factors relating
to the CF registry, such as left-censoring, selective dropout due to death, and
reduced power to detect effects in the adult age range due to the smaller numbers of
individuals in the analysis (Taylor-Robinson 2013).
The Effect of Socioeconomic Status on Treatment
and Healthcare Use in the UK
Use of IV antibiotic therapy for the treatment of respiratory infections, and clinical
exacerbations is a major treatment modality in CF. Longitudinal analysis showed
that people in the UK from more deprived areas are about twice as likely to receive
IV antibiotics in a particular year, after adjustment for disease severity, on the basis
of %FEV1 and P. aeruginosa colonisation status (Odds ratio 2.52, 95 % CI 1.92–
3.17 in the <18 age group, and OR 1.89, 95 % CI 1.51–2.38 in the adult age group,
comparing most to least deprived quintiles) (Table 5.1, Fig. 5.6). This apparent
positive discrimination persists across the age range, from infancy up to 40 years
of age. Furthermore if children and adults with CF are recorded as having any
IV therapy in a particular year, then people from most deprived areas in the UK,
compared to the least, are more likely to have more treatment days (more intensive
treatment), after adjusting for disease severity (15.9 % more days in the paediatric
age group, 95 % CI 8.2–24, and 10.6 % more days in the adult age group 95 %
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Fig. 5.6 Use of therapies: any IV antibiotic therapy, home IV antibiotic therapy, hospital IV
antibiotic therapy, supplemental feeding, DNase, and inhaled antibiotics, by age comparing
extremes of deprivation quintile (Source: Adapted from Taylor-Robinson et al. 2013a)
CI 2.5–19.2). Disaggregating the use of any IV antibiotics into use of therapies at
home, and in hospital, demonstrated that the positive discrimination in use of any
IV therapy was almost entirely due to delivery of these therapies in hospital, as
opposed to home-based treatment. Overall, children from more affluent areas were
more likely to be treated at home compared to their more disadvantaged counterparts
(Fig. 5.6).
The picture is similar for nutritional therapies, with people from more deprived
areas of the UK with CF being more likely to be treated with nutritional therapies,
after adjustment for nutritional status, measured on the basis of BMI SD score (OR
1.78, 95 % CI 1.42–2.2 in the <18 age group, and OR 2.38, 95 % CI 1.69–3.36 in
the adult age group, comparing the most to the least deprived quintiles).
A different pattern is observed when it comes to use of long term inhaled
therapies such as DNase and inhaled antibiotics. There was evidence of inequality
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in the delivery of inhaled therapies to the UK CF population, after adjusting for
measures of disease severity (Table 5.1, Fig. 5.6). Furthermore, this association
becomes stronger in the adult age range. In children, there was no association
between DNase use and deprivation, prior to adjustment for disease severity.
However, after adjustment for disease severity, there was an apparent inequality,
suggesting that DNase may not be delivered equitably in children. This analysis
was clear in the adult population in both the unadjusted and adjusted associations,
with adults from more affluent areas being more likely to report using DNase or
inhaled antibiotics in the preceding year.
With regard to the major treatments for CF, the UK studies provide evidence of
more intensive treatment being delivered to both children and adults with CF, for two
major pillars of CF care – treatment with IV therapies, and nutritional therapies –
after adjusting for measures of disease severity. These findings provide evidence of
a so-called ‘pro-poor’ bias (Ravallion 2001). Aside from the possibility of residual
confounding by severity, one explanation for these findings is that clinicians in
the UK are actively taking steps to address, and overcome the perceived excess
disadvantage faced by people living in more deprived areas. This may be particularly
the case with regard to paediatric care which may be delivered more intensively,
and in a hospital setting, to children with CF who are perceived to be living in
more disorganised home circumstances, where there may be additional barriers to
ensuring that they receive the care and treatments needed (Gupta et al. 2009). More
intensive delivery of treatment to more disadvantaged children may further play a
role in the reduction in weight inequality over the first few years of life, and the
relatively stable inequalities gap demonstrated in the UK studies, as opposed to a
finding of increasing inequality.
Longitudinal Employment Status in People with CF
People with chronic illnesses face numerous barriers to entering the labour market,
and CF provides a case in point. Factors related to disease severity, such as reduced
lung function may restrict employment choices for adults with CF, and the treatment
burden further compounds this; adults with CF are generally expected to perform
physiotherapy regularly and there are the added demands of taking large numbers
of therapies, including frequent visits to hospital (Sawicki et al. 2009).
The analysis of the UK Registry shows that at any one time, about 50 % of the UK
CF population was recorded as being in full or part-time employment for all ages,
but patterns differed by age, sex, and deprivation status. In a longitudinal analysis,
all other things being equal, people from more disadvantaged areas in the UK were
less likely to be in employment, and furthermore, social deprivation was found to
modify the effect of disease severity in CF: poor lung function, as measured by lower
lung function (%FEV1), is more harmful to employment chances for people living
in the most disadvantaged circumstances compared to the least (Fig. 5.7, Table 5.2).
A fall in lung function in people with CF has more of an effect on employment
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Fig. 5.7 Longitudinal employment trajectory versus age, demonstrating the interaction between
deprivation and %FEV1. The lines show the final modelled longitudinal contrasting the adjusted
effects of deprivation, and %FEV1. Low %FEV1is more damaging to employment chances in
people living in the most disadvantaged areas. Other covariates in the final model are fixed
(Adapted from Taylor-Robinson et al. 2013b)
Table 5.2 Percentage of people with CF in employment at age 30
Employment (%) Employment (%)
Men Women
No health or social disadvantage
(good lung function and high SES)
69  2 66  8
Health disadvantage only (poor
lung function and high SES)
66  1 63  7
Social disadvantage only (good
lung function and low SES)
54  1 51  4
Double disadvantage (poor lung
function and low SES)
46  4 43  6
Adapted from Taylor-Robinson (2013)
%FEV1 fixed at 80 percentage points for good lung function, and 40 percentage points for poor
lung function
High SES fixed at least deprived quintile, and low SES fixed at most deprived quintile
chances in disadvantaged populations – at the age of 30, a contrast of 40 percentage
points in lung function corresponds to a decline in employment prevalence from
69.2 to 66.1 % (3.1 percentage points difference) for men in least deprived quintile,
compared to a change from 54.1 to 46.4 % (7.7 percentage points difference) in the
most deprived quintile (Table 5.2).
The social consequences of having a chronic disease such as CF are important,
and understudied. Although social conditions do not influence the risk of having CF,
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there are significant differences in outcomes such as growth and lung function, and
ultimately survival, in people with CF in the UK and US (Taylor-Robinson et al.
2013a; Schechter et al. 2001; Barr and Fogarty 2011). The analysis of UK data
presented here suggests that people with the double burden of chronic illness and
low SES are more likely to be excluded from the labour market. This in turn is likely
to lead to an increased risk of poverty, social exclusion, and further adverse effects
on health. In this way, the differential social consequences of illness in the context
of CF, represents an important pathway for the amplification of health inequalities
over the life course (Taylor-Robinson et al. 2013b).
Social Inequalities, Even for Genetic Diseases
The analyses of the UK CF registry presented here demonstrate that people from
more disadvantaged areas in the UK have worse health and social outcomes than
their more affluent counterparts. They are more likely to have poor growth, poorer
lung function, and to acquire P. aeruginosa, and are less likely to be in employment.
In contrast, the use of major therapies in the UK CF population shows a so called
‘pro-poor’ bias, with people living in the most deprived areas of the UK around
twice as likely to be treated with IV antibiotics and nutritional therapies, after
adjusting for disease severity. However, there was evidence of inequalities in the use
of home IV therapies, DNase, and inhaled antibiotics. With regard to employment
outcomes the analyses demonstrate that deprivation modifies the effect of disease
severity in CF: poor lung function is more harmful to employment chances for
people living in the most disadvantaged circumstances compared to the least.
CF is the archetypal classically inherited genetic disease, caused by a single gene
defect that is both a necessary and sufficient cause of a chronic illness. CF was
one of the first diseases for which the precise genetic mechanism was elucidated,
with the sequencing of the CFTR gene, and yet knowledge of the genetic mutation
does not predict clinical outcome (Kerem et al. 1990; Schechter 2004). Despite
the genetic origin of CF, the evidence presented here shows that outcomes in CF
are socially patterned, demonstrating that social factors are leading to profound
differences in the course of the illness, which cannot be explained by genetic
differences.
Inequalities from the Start
The finding that inequalities start early in the life course for people with CF and
then track through until later life, even for a genetic disease like CF, supports the
growing evidence around the early origins of health inequalities. The convergence
between the inequalities literature, and the current direction of CF research is also
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striking, whereby both disciplines are suggesting that the early years are critical. In
their recent piece on early lung disease, for instance, Grasemann and Ratjen state
(Greasemann and Ratjen 2013):
The infant and preschool age could represent a unique period of opportunity to postpone or
even prevent the onset of cystic fibrosis lung disease.
Compare this to possibly the key recommendation of the UK Marmot review
(Marmot et al. 2010):
Action to reduce health inequalities must start before birth and be followed through the life
of the child. Only then can the close links between early disadvantage and poor outcomes
throughout life be broken.
The findings presented here support the growing consensus that early disadvan-
tage tracks forward, to influence adult health in later life, and that children who start
behind tend to stay behind (Marmot et al. 2010; Kuh et al. 2004; Galobardes et al.
2008). This has important implications for public health policy, and suggests that
children may have optimum or sub-optimum trajectories on the basis of early life
experiences. As Fig. 5.8 below illustrates, these early life trajectories can determine
the point at which an individual becomes symptomatic for a particular adult chronic
disease. Interventions to targeted in the early years may delay the onset of limiting
illness in later life.
The Y-axis in Fig. 5.8 represents some general phenomena relating to health
development. For instance, this model has been applied to the development of lung
health (Kuh et al. 2004), mental health capacity (Kirkwood et al. 2008), and features
in a recent Lancet paper in a very similar form with ‘behavioural competence’ on
the Y-axis (Walker et al. 2011).
Fig. 5.8 How risk reduction and health promotion strategies influence health development
(Adapted from Halfon et al. 2000)
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Health Services and Heath Inequalities in CF
The findings presented here have demonstrated variations in the recorded use of
treatments by SES for people with CF in the UK NHS. What do these findings tell
us more broadly about the role of health services and their role in mitigating or
potentiating health inequalities?
An important starting point is to understand what equity in healthcare might
look like? Restating Margaret Whitehead’s definition, equity in healthcare can be
seen as being multifaceted and incorporating ideas about: fair arrangements that
allow equal geographic, economic and cultural access to available services for all
in equal need of care. The end goal of equity in health care would be to closely
match services to the level of need. This may very well result in large differences in
access and use of services between different socioeconomic groups, favouring the
more disadvantaged groups in greatest need (Whitehead and Dahlgren 2007).
Need, in the context of the definition above, can be taken to relate not just to
disease severity, but also to disadvantage. On this basis one can argue that equity is
being achieved for certain aspects of CF care in the NHS, since the data suggests
that clinicians are responding to both disease severity, and level of disadvantage
when making treatment decisions.
The Commission on Social Determinants of Health highlights that inequitable
delivery of health care is an important factor in the generation of health inequalities
(CSDH 2008). Whilst health services are generally not the cause of health inequal-
ities (Marmot et al. 2010), they can play an important role in the amplification and
perpetuation of disadvantage in a number of ways, for example through the so-called
‘inverse care law’ (Hart 1971) or the ‘medical poverty trap’ in health care systems
that are not free at the point of access (Whitehead et al. 2001). The famous inverse
care law, described by the British GP Tudor Hart (Hart 1971) states:
The availability of good medical care tends to vary inversely with the need for it in the
population served. This inverse care law operates more completely where medical care is
exposed to market forces, and less so where such exposure is reduced.
This describes the situation whereby those who most need high quality health
care, end up receiving less and/or lower quality care. For this reason, striving for
equity in health service delivery, as defined by equal use for equal need (Whitehead
and Dahlgren 2007), is a central principle for health care systems (Whitehead 1990),
including in the NHS.
In the UK, the Darzi report noted the relationship between low SES and poor
health and suggested that the NHS has a pivotal role in providing excellent services
as “a matter of fairness” (Darzi 2008). The controversial new Health and Social
Care Act further enshrines in legislation explicit duties on the Secretary of State,
NHS Commissioning Board and clinical commissioning groups (CCGs) to have
regard to the need to reduce inequalities in access to, and to the outcomes of
healthcare (DH 2012). Many dissenting voices have suggested the legislation is
likely to have significant adverse effects on health inequalities (FPH 2010; Pollock
et al. 2012a, b; Whitehead et al. 2010). While this may well be the case, the
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wording of the legislation could serve as a lever to hold those responsible for
health services to account in terms of taking action to reduce inequalities in
outcomes. In these troubled times for the NHS in the UK, the findings presented
here provide some evidence that the system of care in CF can take into account
the extra needs of disadvantaged children and their families in the UK to deliver
care that may be effective in reducing, or at least limiting an increase in health
inequalities.
The analysis also sheds some light on potential differences between the delivery
of chronic care for children versus that delivered to adults, by demonstrating an
increasing propensity to inequality in delivery of both inhaled CF treatments in the
adult population, as compared to the paediatric age group. This corroborates the
broader literature, in terms of access to and use of care in chronic diseases, which
suggests a different picture in adults and children: In adults, a systematic review of
universal health care systems by Hanratty et al. suggested a decline in need adjusted
use with increasing deprivation, especially in use of specialist hospital services, but
reasonably equitable access to primary health care (Hanratty et al. 2007). A more
recent European study found large inequalities in the utilisation of specialist care for
chronic diseases, which were not compensated by utilisation of GP services (Stirbu
et al. 2011). The analysis of CF Registry data from the UK demonstrated a mixed
picture for adults, with marked pro-poor bias for IV and nutritional therapies, but
inequality in the use of inhaled therapies.
This contrasts with analyses of children’s use of health services in the UK,
where the studies have tended to show increased use with lower SES, and arguably
equitable delivery of care in the studies that have adjusted for need, notwithstanding
the difficulties of undertaking precise adjustment. Cooper et al. found no evidence
that children and young people’s use of health services varied according to their
SES, in an analysis that adjusted for need on the basis of self-reported health
status, a rather crude measure, in an analysis of the British General Household
survey (Cooper et al. 1998). Saxena et al. demonstrated increased use of primary
care for disorders such as infections, asthma, and injuries and poisonings in
children with lower SES (Saxena et al. 1999). In a further study by the same
author, children’s use of primary and secondary health services reflected health
status rather than SES, and on this basis the authors suggest that equity of access
has been partly achieved (Saxena et al. 2002). A more recent study in the UK
demonstrated a clear association between adverse socioeconomic position at the
time of birth and increased hospital inpatient admissions, days, and costs during the
first 10 years of life (Petrou and Kupek 2005). A further study of children in Nordic
countries demonstrated equitable access to primary care, but inequality in use of
specialist hospital services after careful adjustment for health status on the basis of
questionnaire data (Halldorsson et al. 2002).
It remains unclear whether the increasing inequality observed in use of inhaled
treatments in CF in adults reflects general differences between paediatric and adult
care for chronic disease, or is specific to differences in the CF model of care, perhaps
explained by the potential for paediatricians to act in a more paternalistic manner
towards the children in their care, in contrast to the relationship between an adult
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patient and the CF care team, where adult patients can ‘vote with their feet’. Further
studies should focus on identifying aspects of CF care in children, and adulthood
that may be important in reducing health inequalities.
What Are the Implications for Policy and Clinicians?
For individual clinicians, social deprivation needs to be considered as a major risk
factor for poor outcomes in CF, and appropriate responses to remediate against the
adverse effects of deprivation should be developed. An important first step is to
acknowledge and measure the problem. Without on-going data collection to monitor
health inequalities, there can be no policy response.
There are a number of steps that could be taken to influence differential
exposures. One obvious target for action is to protect newly diagnosed children from
environmental tobacco smoke exposure (ETS), since this may be the single most
important explanatory factor for SES-related inequalities in this disease (Taylor-
Robinson and Schechter 2011). Early identification of family members who smoke,
collection of that data in the registry, and appropriate counselling and referral
to smoking cessation services would be an effective intervention for all patients
regardless of social position.
The UK analysis presented in this chapter also suggests differential exposure to
P. aeruginosa acquisition, and this requires further investigation. One concern is that
this may relate to hospital-acquired acquisition of P. aeruginosa, from other patients
with CF, as a result of more time spent in hospital. An appropriate policy response
might be to ensure that mechanisms are put in place to facilitate equitable delivery of
treatments at home, wherever possible. Home care has been shown to be as effective
as hospital treatment for some patients (van Aalderen et al. 1995), but not others
(Bosworth and Nielson 1997; Thornton et al. 2005). It is also less expensive and may
be associated with improvement in quality of life (van Aalderen et al. 1995). Access
to appropriate home care may also mean that children are less likely to miss school,
which is important in terms of reducing the differential consequences of ill health.
There are some further steps that individual clinicians and teams could take to
reduce children’s exposure to poverty, and its consequences. Whilst beyond the
scope of full discussion here, an increased focus on a whole family approach to
the care of the child with CF, with appropriate involvement of the full range of
social services support available to children and families living in disadvantaged
circumstances, may help to mitigate some of the effects of social deprivation.
This would include supporting parents to access all the benefits and services that
they are entitled to, and working to reduce any perceived stigma associated with
using these services. Support with the additional costs of childcare, travel to clinic
appointments, and any additional medical expenditure would also help reduce the
financial burden on the most disadvantaged families. This should be coupled with
support to develop patient and family disease self-management skills (Smith and
Goldman 2010; Goldman and Smith 2002).
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Social workers, and other members of the multidisciplinary CF team have an
important role in helping people with CF navigate the welfare system, so that they
are clear about the benefits that they are entitled to, and the support available to
help people with chronic illness in the workplace. This is particularly important at
the moment, in the context of the widespread changes to the welfare and benefits
system in the UK, with the drive to reduce the number of people claiming Disability
Living Allowance. A recent study by Nash et al. demonstrated that the majority
of adult patients with CF claim some benefits, and the majority of these were
concerned about the planned reforms (Nash et al. 2011). Furthermore, the concerns
of the CF community regarding the changes to the welfare system were outlined
in a submission by the CF Trust to the Department of Work and Pensions (2011).
Further efforts are required to identify effective workplace, rehabilitation, and other
interventions to reduce the employment disadvantage experienced by people with
CF, particularly for those from more disadvantaged areas.
A key question for practicing physicians raised by our studies is what role health
care delivery plays in mitigating or potentiating health inequalities in CF. In the
UK, we have demonstrated a mixed picture, and action is required to understand the
inequalities in access to inhaled therapies uncovered, and to promote the pro-poor
delivery of care demonstrated for other treatments, that may be effective in limiting
increases in outcome inequality over time. The potential utility of systematically
targeting more intensive therapy at children living in disadvantaged circumstances
should be investigated further (Gupta et al. 2009). The adoption of system-based
methods to optimize consistency in the use of best care practices might help further
minimize variations in prescribed care (Schechter et al. 2009). Furthermore, the
early appearance of inequalities, and the potential for decreasing inequality in
weight in the first few years of life, focusses policies on the early years, and provides
support for new-born screening programmes in CF.
Ultimately, however, while individually focussed interventions may be of some
limited success, the long term solution to health inequalities in people with CF
and in the general population is likely to be one that takes broader action to
address the “social determinants of health” (CSDH 2008). These are the “con-
ditions in which we are born, grow up, work and live”, and include income and
income distribution, education, employment and working conditions, housing, food
insecurity, race/ethnicity, and gender roles. These factors provide a particularly
important context for a family dealing with the stresses of caring for a child with a
complex chronic illness like CF over a lifetime. The evidence is clear, unfortunately,
that we have made little progress over the last few decades in reducing health
inequalities (Marmot et al. 2010). However, the analysis presented in this chapter
provides further evidence that the early years represent the key period for targeting
interventions to reduce inequalities. An important place to start would be to renew
efforts in the UK to reduce children’s exposure to poverty, by for instance (Marmot
et al. 2010):
• maximising household incomes, by helping parents into employment;
• providing affordable housing;
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• providing affordable, high quality child care;
• providing affordable public transport;
• helping families manage debt;
• providing better social security support for families caring for children with
chronic illness.
With reference to Fig. 5.8 above, policy makers should also act to reduce any
inequitable distribution of health damaging and health promoting exposures over the
course of children’s lives. Reducing the consequences of poverty by focussing on
child development in the early years is a good place to start. Actions could involve
(Marmot et al. 2010; Field 2010):
• protecting investment in the early years in the face of budget cuts in the UK;
• shifting expenditure towards the early years wherever possible;
• providing high quality and consistent support and services for parents during
pregnancy;
• providing high quality universal services in childhood;
• supporting families to achieve progressive improvements in early child develop-
ment, by providing good quality early years education and childcare;
• providing support so that all children can access a healthy diet in the early years;
• providing high quality home visiting services;
• focussing on narrowing the educational attainment gap at all stages.
As health deteriorates, the ability of people to remain in education and employ-
ment declines. Being out of work increases the risk of poverty and social exclusion,
and is likely to further damage the health of the most disadvantaged. Actions to
address differential social consequences could include (Holland et al. 2011):
• supporting people with chronic illness to find appropriate employment, with a
focus on active labour market policies;
• providing better in-work social security support for people with chronic illness.
Conclusions
CF is the commonest serious inherited disease among Caucasian populations.
Intensive support from family and health care services is needed from the time
of diagnosis onwards, and most patients die prematurely from respiratory failure.
There have been astounding improvements in survival over successive birth cohorts
in CF, such that it is estimated that British children born in the twenty-first century
will have a median survival of over 50 years of age (Dodge et al. 2007). However,
there remains a great deal of variation in disease progression and survival in CF,
much of which is related to social and environmental rather than genetic determi-
nants (Schechter 2004). Most pointedly, it has been known for over 20 years (Britton
1989) that people with CF from socio-economically disadvantaged backgrounds die
younger than those in more advantaged positions.
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CF offers a valuable case for understanding how health inequalities develop.
It is an autosomal recessive disease with an asymptomatic (and, until recently,
undetectable) carrier state, so unlike many other diseases, SES does not influence
who gets CF. SES-related outcome inequalities develop due to the different patterns
of exposure to harmful and protective or therapeutic influences over the course
of people’s lives. Studies from the US and UK show that significant inequalities
in key intermediate CF outcomes such as growth and lung function begin early
in childhood (Taylor-Robinson et al. 2013a; Schechter et al. 2001; O’Connor
et al. 2003) and then persist over time. The early appearance and persistence of
inequalities supports the need for interventions that are targeted at the early (and
perhaps prenatal) years.
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